Sorafenib (D3)
Cat. No.：YN350018
| 产品名称: | Sorafenib (D3) |
| CAS No.: | 1130115-44-4 |
| Chemical Name: | 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(methyl-d3)-2-pyridinecarboxamide |
| Synonyms: | Bay 43-9006 (D3) |
| 分子量: | 467.84 |
| 分子式: | C₂₁H₁₃D₃ClF₃N₄O₃ |
| SMILES: | O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1)NC([2H])([2H])[2H] |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Sorafenib D3 (Bay 43-9006 D3) 是 Sorafenib 的氘代化合物。Sorafenib 是一种多激酶抑制剂，抑制 Raf-1，B-Raf 和 VEGFR-3 的 IC50分别为6 nM，20 nM，22 nM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Lyons, J.F., Wilhelm, S., Hibner, B., et al.Discovery of a novel Raf kinase inhibitorEndocr. Relat. Cancer8(3),219-225(2001)
Wilhelm, S.M., Carter, C., and Tang, L.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res.64(19),7099-7109(2004)
Liu, L., Cao, Y., Chen, C., et al.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res.66(24),11851-11858(2006)
Murphy, D.A., Makonnen, S., Lassoued, W., et al.Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)Am. J. Pathol.169(5),1875-1885(2006)
Dixon, S.J., Patel, D.N., Welsch, M., et al.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosisElife3,e02523(2014)
Himmelsbach, K., Sauter, D., Baumert, T.F., et al.New aspects of an anti-tumour drug: Sorafenib efficiently inhibits HCV replicationGut58(12),1644-1653(2009)
